NASDAQ:SUPN   Supernus Pharmaceuticals, Inc.
What used to be a resistance now a support.
Plus an inverse head & shoulders.
Plus positive news: “Supernus said that a Phase 3 trial 'met the primary endpoint ... compared to placebo in improving the symptoms of ADHD.'"
Going long anticipating 30’s where MA200 is and then maybe higher.
With tight stop-loss just behind the support.
Comment:
Going to test 24.5 support
If it stands it, it might then go to the second target which is at around 50
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.